Marc N. Casper, chairman and CEO, has been an active seller in Thermo Fisher Scientific (TMO) over the past month. Between August 7 and August 24, 2026, his Form 4 filings show 22 open-market sale transactions. These sales totaled more than $12.醋fox$12 million alone for that stretch, with individual sales ranging from roughly $20,000 on August 24 to $1.89 million on August 21. The filings also list option exercises (code M) on August 20 and 21, each valued at $3.096 million, which typically provide the shares sold. Across all his recorded activity, Casper has sold $147.9 million worth of stock against just $439,086 in open-market purchases, a ratio that places his posture firmly on the sell side.
The transaction pattern traces back to at least two companies, but the recent concentration in TMO is clear. On August 20 alone, Casper filed nine sale transactions with a combined value near $6.15 million. That volume continued on August 21 with five sales worth roughly $6.27 million, and on August 24 with four sales valued at about $172,438. The last buy on record is not in the recent window; his total purchase figure of $439,086 is dwarfed by the scale of the sells, and no acquisitions (code A) or issuer buybacks (code D) appear in the data.
What the pattern reveals is straightforward: Casper is monetizing exercised options through sustained secondary-market sales. The sales are clustered, often multiple per day, and tied to exercise dates, a common combination in executive compensation. He has not made an open-market purchase in the recent period, and his overall buying interest is minimal compared to the selling volume. Over 308 total filings across two companies, the dollar bias is heavily toward sales, with the most recent activity in TMO reinforcing that direction. No recent buy signals appear; the last batch of filings is uniformly sales and exercises.
AI-assisted summary